HDAC6 and glioblastoma: These results suggest that SAHA, VPA, and CAY10603 – particularly as a novel small molecule inhibitor of HDAC6 – hold promise as effective combinatorial treatments for GBM, warranting further preclinical and clinical development, and highlighting the potential of HDACis in overcoming drug resistance in GBM patients.